GlassScriptPhysician profile
Isabelle Louis
NPI 1497530448
$3,235.80
in general payments reported to CMS, 2019-2025
19 companies · $3,018 in 2025
The $3,018 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $217 · 2025: $3,018.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,236.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,235.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $419.37 | 2025 | Wegovy, Ozempic, Rybelsus |
| Xeris Pharmaceuticals, INC. | $408.24 | 2024-2025 | Recorlev, Gvoke Hypopen |
| Ascendis Pharma Endocrinology INC | $336.96 | 2025 | Yorvipath |
| Lilly USA, LLC | $333.31 | 2024-2025 | Jardiance, Zepbound, Mounjaro |
| Insulet Corporation | $294.83 | 2025 | Omnipod, Omnipod |
| Abbott Laboratories | $280.18 | 2025 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $259.99 | 2025 | Jardiance |
| Amgen INC. | $221.58 | 2025 | Tepezza, Evenity, Prolia |
| Amneal Pharmaceuticals LLC | $125.62 | 2025 | Unithroid |
| Medtronic, INC. | $105.62 | 2025 | Minimed 780g |
| Madrigal Pharmaceuticals | $90.47 | 2025 | Rezdiffra |
| Tandem Diabetes Care, INC. | $62.98 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Antares Pharma, INC. | $57.02 | 2025 | Xyosted |
| Recordati_rare_diseases_inc. | $55.82 | 2025 | Isturisa |
| Corcept Therapeutics | $45.47 | 2025 | Korlym |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intra-Sana Laboratories | $40.47 | 2025 | Glycate, Reltone 400 Mg, Reltone 200 Mg |
| Sequel Med Tech, LLC | $39.54 | 2025 | Twiist |
| Alexion Pharmaceuticals, INC. | $32.62 | 2024 | Strensiq |
| Sanofi-Aventis U.S. LLC | $25.71 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Isabelle Louis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.